Skip to main content

Table 2 Metabolites associated with each immune-mediated inflammatory disease (IMID) in the discovery and validation cohorts

From: Urine metabolome profiling of immune-mediated inflammatory diseases

IMID/Metabolite

log2(IMID/Ctrl)DISb

P DIS

log2(IMID/Ctrl)VALb

P VAL

P COMB

CD/Citrate

–0.94 (–1.21 to –0.68)

1.4 × 10–8

–0.80 (–1.01 to –0.59)

1.1 × 10–9

6.2 × 10–16

SLE/Citrate

–0.68 (–0.96 to –0.41)

6.1 × 10–5

–0.85 (–1.11 to –0.59)

1.4 × 10–7

2.3 × 10–10

Ps/Citrate

–0.60 (–0.82 to –0.38)

1.0 × 10–5

–0.45 (–0.64 to –0.26)

1.3 × 10–4

2.9 × 10–8

RA/Citrate

–0.49 (–0.72 to –0.26)

5.4 × 10–4

–0.55 (–0.77 to –0.33)

4.3 × 10–5

4.3 × 10–7

PsA/Citrate

–0.39 (–0.63 to –0.16)

6.7 × 10–3

–0.44 (–0.64 to –0.24)

3.7 × 10–4

3.5 × 10–5

UC/Citratea

–0.34 (–0.57 to –0.11)

1.6 × 10–2

–0.39 (–0.59 to –0.19)

1.6 × 10–3

3.0 × 10–4

UC/N-acetyl AAs

–0.57 (–0.85 to –0.30)

7.6 × 10–4

–0.64 (–0.87 to –0.42)

2.4 × 10–6

3.8 × 10–8

RA/N-acetyl AAsa

–0.32 (–0.53 to –0.10)

1.7 × 10–2

–0.61 (–0.86 to –0.37)

4.3 × 10–5

1.1 × 10–5

CD/N-acetyl AAs

–0.63 (–0.90 to –0.36)

1.4 × 10–4

–0.26 (–0.47 to –0.06)

3.7 × 10–2

6.7 × 10–5

Ps/N-acetyl AAs

–0.27 (–0.43 to –0.11)

6.9 × 10–3

–0.35 (–0.54 to –0.15)

3.3 × 10–3

2.6 × 10–4

PsA/N-acetyl AAs

–0.43 (–0.67 to –0.19)

3.9 × 10–3

–0.28 (–0.46 to –0.10)

9.1 × 10–3

3.9 × 10–4

Ps/Trigonelline

–0.70 (–0.99 to –0.40)

1.0 × 10–4

–0.73 (–0.94 to –0.51)

7.3 × 10–8

2.0 × 10–10

UC/Trigonelline

–0.56 (–0.88 to –0.25)

3.3 × 10–3

–0.72 (–0.95 to –0.48)

7.3 × 10–7

5.0 × 10–8

CD/Trigonelline

–0.71 (–1.01 to –0.41)

1.3 × 10–4

–0.54 (–0.75 to –0.32)

3.8 × 10–5

1.0 × 10–7

PsA/Trigonellinea

–0.46 (–0.74 to –0.18)

7.5 × 10–3

–0.42 (–0.63 to –0.21)

1.1 × 10–3

1.0 × 10–4

SLE/Alanine

–0.29 (–0.44 to –0.14)

1.5 × 10–3

–0.62 (–0.75 to –0.49)

4.8 × 10–14

2.7 × 10–15

Ps/Alanine

–0.31 (–0.45 to –0.16)

4.2 × 10–4

–0.35 (–0.46 to –0.25)

6.5 × 10–8

7.0 × 10–10

PsA/Alaninea

–0.17 (–0.31 to –0.04)

4.0 × 10–2

–0.37 (–0.47 to –0.26)

4.0 × 10–8

3.4 × 10–8

RA/Alanine

–0.24 (–0.38 to –0.10)

5.3 × 10–3

–0.35 (–0.46 to –0.24)

4.4 × 10–7

4.9 × 10–8

CD/Alaninea

–0.23 (–0.38 to –0.08)

1.2 × 10–2

–0.21 (–0.32 to –0.11)

6.7 × 10–4

1.1 × 10–4

SLE/Methylsuccinatea

–0.72 (–1.25 to –0.19)

2.5 × 10–2

–2.10 (–2.61 to –1.59)

5.0 × 10–11

3.6 × 10–11

UC/Methylsuccinate

–1.09 (–1.58 to –0.60)

2.9 × 10–4

–0.61 (–1.01 to –0.22)

1.1 × 10–2

4.5 × 10–5

CD/Methylsuccinate

–1.05 (–1.56 to –0.54)

7.4 × 10–4

–0.67 (–1.08 to –0.26)

7.6 × 10–3

7.4 × 10–5

PsA/Methylsuccinatea

–0.74 (–1.25 to –0.23)

1.6 × 10–2

–0.91 (–1.35 to –0.47)

6.7 × 10–4

1.4 × 10–4

Ps/Methylsuccinate

–0.95 (–1.49 to –0.40)

4.7 × 10–3

–0.63 (–1.07 to –0.20)

1.7 × 10–2

8.3 × 10–4

UC/Unknown 7

5.49 (4.72 to 6.26)

2.2 × 10–26

5.30 (4.68 to 5.93)

1.5 × 10–36

4.7 × 10–60

CD/Unknown 7

2.40 (1.61 to 3.20)

1.0 × 10–6

2.75 (2.14 to 3.36)

5.1 × 10–13

2.3 × 10–17

RA/Unknown 7

1.68 (0.99 to 2.37)

7.6 × 10–5

1.48 (0.94 to 2.02)

8.2 × 10–6

1.4 × 10–8

SLE/Unknown 7a

0.81 (0.18 to 1.44)

3.4 × 10–2

1.33 (0.80 to 1.86)

4.8 × 10–5

2.3 × 10–5

CD/Hippurate

–1.74 (–2.08 to –1.40)

1.5 × 10–15

–1.54 (–1.80 to –1.28)

4.5 × 10–20

5.5 × 10–33

UC/Hippurate

–1.03 (–1.32 to –0.73)

3.3 × 10–8

–0.92 (–1.16 to –0.69)

3.8 × 10–10

4.9 × 10–16

Ps/Hippuratea

–0.40 (–0.66 to –0.13)

1.6 × 10–2

–0.33 (–0.54 to –0.11)

1.4 × 10–2

2.0 × 10–3

RA/Carnitinea

–0.68 (–1.11 to –0.25)

9.2 × 10–3

–1.05 (–1.35 to –0.75)

2.1 × 10–8

4.4 × 10–9

PsA/Carnitinea

–0.55 (–0.98 to –0.11)

3.9 × 10–2

–0.80 (–1.11 to –0.50)

2.0 × 10–5

1.2 × 10–5

CD/3-Hydroxyisovalerate

–1.02 (–1.51 to –0.53)

6.7 × 10–4

–1.88 (–2.27 to –1.48)

4.2 × 10–14

1.1 × 10–15

UC/Phenylacetylglycine

0.42 (0.19 to 0.65)

2.5 × 10–3

0.48 (0.31 to 0.65)

5.5 × 10–6

2.7 × 10–7

CD/Free acetatea

–0.46 (–0.80 to –0.11)

3.0 × 10–2

–0.51 (–0.71 to –0.30)

6.5 × 10–5

2.8 × 10–5

RA/Tyrosine

1.25 (0.60 to 1.90)

1.7 × 10–3

0.57 (0.14 to 1.00)

3.0 × 10–2

5.7 × 10–4

CD/N,N-dimethylglycinea

–0.27 (–0.46 to –0.07)

2.3 × 10–2

–0.25 (–0.44 to –0.06)

2.8 × 10–2

5.5 × 10–3

  1. Association statistics for the discovery (DIS), the validation (VAL) and the combined (COMB) cohorts. aNominal association
  2. bLogarithmic concentration ratios (median, 95 % CI) of the corresponding IMID cohort versus the control cohort
  3. CD, Crohn’s disease; N-acetyl AAs, N-acetyl amino acids; Ps, psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; UC, ulcerative colitis